Clinical Trials Browser

NCT03410615 2026-03-24

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Phase 2 Active not recruiting

129 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Phase 2 Active not recruiting

18 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

NCT03726775 2025-05-07

REWRITe

Phase 2 Active not recruiting

61 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06446570 2024-06-06

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Phase 2 Completed

18 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

Phase 2 Completed

104 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03691714 2023-12-08

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

36 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

340 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03624231 2023-08-31

DURTRE-RAD

Phase 2 Completed

18 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03737968 2023-03-21

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Phase 2 Unknown

48 enrolled

Head & Neck

Laryngeal Diseases

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04001413 2022-07-29